Moreover, we developed and characterized WQQ-345 as a novel BCAT1-targeted inhibitor, and demonstrated its in vitro and in vivo antitumor efficacy against TKI-resistant NSCLC tumors. This evidence concerns the gene BCAT1 and non-small cell lung carcinoma.